A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
Launched by CITY OF HOPE MEDICAL CENTER · Jun 2, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called mogamulizumab on patients with certain types of skin lymphomas, specifically mycosis fungoides and Sezary syndrome. One of the common side effects of this treatment is a rash known as mogamulizumab-associated rash (MAR). The goal of the study is to understand this rash better and to distinguish it from the worsening of the disease itself. This is important because if doctors mistakenly think the rash means the treatment isn’t working, they might stop the medication too early.
To participate in the trial, you need to be an adult (18 years or older) who has been diagnosed with relapsed or refractory mycosis fungoides or Sezary syndrome and has been chosen by your doctor to start mogamulizumab treatment. Participants will be asked to sign a consent form, undergo some skin tests, and provide blood samples at the beginning of the study and if they develop a rash. This research could help improve how doctors manage treatment for patients with these conditions, ensuring they get the best care possible.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \* Adult patients (\>= 18 years of age) diagnosed with relapsed/refractory Mycosis Fungoides (MF) stage IB, IIA, IIB, III and IV or Sezary Syndrome(SS), and selected by their treating physician to receive single agent mogamulizumab (newly initiated)
- • Signed informed consent
- • Willing to undergo baseline biopsy and during treatment to evaluate for Mogamulizumab-Associated Rash (MAR) if clinically indicated
- • Willing to provide blood sample at baseline, and if applicable, at onset of Mogamulizumab-Associated Rash (MAR)
- Exclusion Criteria:
- • \* Other concomitant systemic and skin directed Cutaneous T-cell Lymphoma (CTCL) regimens except for topical steroids
- • Prior treatment with mogamulizumab
About City Of Hope Medical Center
City of Hope Medical Center is a leading research and treatment institution located in Duarte, California, dedicated to advancing innovative therapies and improving patient outcomes in the fields of cancer, diabetes, and other life-threatening diseases. With a strong emphasis on translational medicine, City of Hope combines cutting-edge research with compassionate care, fostering a collaborative environment for clinical trials that aim to bring new treatments from the laboratory to the bedside. The center is recognized for its commitment to patient-centered care and its role as a National Cancer Institute-designated Comprehensive Cancer Center, making it a pivotal player in the landscape of medical research and clinical innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Duarte, California, United States
Houston, Texas, United States
Tampa, Florida, United States
Philadelphia, Pennsylvania, United States
Palo Alto, California, United States
Atlanta, Georgia, United States
Baltimore, Maryland, United States
Seattle, Washington, United States
Saint Louis, Missouri, United States
Patients applied
Trial Officials
Christiane Querfeld
Principal Investigator
City of Hope Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported